Brain scans could reveal which MS drugs fight mental exhaustion

NCT ID NCT04448977

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This study investigates whether disease-modifying medications for relapsing-remitting multiple sclerosis (RRMS) can reduce cognitive fatigue—the tiredness that follows intense mental effort. Researchers will use functional MRI to measure brain activation in people starting either Ocrevus or Copaxone, comparing them to healthy volunteers. The goal is to identify a brain-based biomarker that tracks fatigue, which could help personalize MS treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Ocrevus (ocrelizumab) and Copaxone (glatiramer acetate)
What this could lead to
If successful, this could lead to a brain-imaging biomarker that helps doctors choose MS treatments that better manage cognitive fatigue.
What could go wrong
This is a small, early-stage study (24 participants) that measures brain activity, not long-term outcomes. Results may not apply to all MS patients, and the medications may have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS, RELAPSING-REMITTING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Kessler Foundation

    West Orange, New Jersey, 07052, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.